![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: C3orf33 |
Gene summary for C3ORF33 |
![]() |
Gene information | Species | Human | Gene symbol | C3orf33 | Gene ID | 285315 |
Gene name | chromosome 3 open reading frame 33 | |
Gene Alias | AC3-33 | |
Cytomap | 3q25.31 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q6P1S2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
285315 | C3orf33 | LZE4T | Human | Esophagus | ESCC | 2.83e-02 | 1.17e-01 | 0.0811 |
285315 | C3orf33 | P2T-E | Human | Esophagus | ESCC | 1.59e-33 | 6.04e-01 | 0.1177 |
285315 | C3orf33 | P4T-E | Human | Esophagus | ESCC | 4.52e-21 | 3.67e-01 | 0.1323 |
285315 | C3orf33 | P5T-E | Human | Esophagus | ESCC | 2.75e-05 | 7.94e-02 | 0.1327 |
285315 | C3orf33 | P8T-E | Human | Esophagus | ESCC | 6.81e-13 | 2.28e-01 | 0.0889 |
285315 | C3orf33 | P10T-E | Human | Esophagus | ESCC | 4.26e-09 | 2.07e-01 | 0.116 |
285315 | C3orf33 | P12T-E | Human | Esophagus | ESCC | 1.47e-14 | 1.82e-01 | 0.1122 |
285315 | C3orf33 | P15T-E | Human | Esophagus | ESCC | 4.85e-10 | 1.83e-01 | 0.1149 |
285315 | C3orf33 | P16T-E | Human | Esophagus | ESCC | 5.79e-17 | 3.00e-01 | 0.1153 |
285315 | C3orf33 | P20T-E | Human | Esophagus | ESCC | 1.50e-02 | 1.39e-01 | 0.1124 |
285315 | C3orf33 | P22T-E | Human | Esophagus | ESCC | 1.08e-10 | 2.15e-01 | 0.1236 |
285315 | C3orf33 | P23T-E | Human | Esophagus | ESCC | 2.45e-05 | 1.42e-01 | 0.108 |
285315 | C3orf33 | P26T-E | Human | Esophagus | ESCC | 1.40e-10 | 1.71e-01 | 0.1276 |
285315 | C3orf33 | P27T-E | Human | Esophagus | ESCC | 4.12e-07 | 1.41e-01 | 0.1055 |
285315 | C3orf33 | P28T-E | Human | Esophagus | ESCC | 2.31e-09 | 2.13e-01 | 0.1149 |
285315 | C3orf33 | P30T-E | Human | Esophagus | ESCC | 1.59e-04 | 2.41e-01 | 0.137 |
285315 | C3orf33 | P36T-E | Human | Esophagus | ESCC | 2.00e-03 | 1.64e-01 | 0.1187 |
285315 | C3orf33 | P47T-E | Human | Esophagus | ESCC | 4.13e-02 | 5.57e-02 | 0.1067 |
285315 | C3orf33 | P48T-E | Human | Esophagus | ESCC | 3.67e-04 | 8.48e-02 | 0.0959 |
285315 | C3orf33 | P54T-E | Human | Esophagus | ESCC | 2.12e-05 | 1.83e-01 | 0.0975 |
Page: 1 2 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![]() | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00510908 | Esophagus | ESCC | regulation of DNA-binding transcription factor activity | 252/8552 | 440/18723 | 5.22e-07 | 6.97e-06 | 252 |
GO:0043409110 | Esophagus | ESCC | negative regulation of MAPK cascade | 105/8552 | 180/18723 | 4.13e-04 | 2.35e-03 | 105 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C3orf33 | SNV | Missense_Mutation | c.262N>C | p.Glu88Gln | p.E88Q | Q6P1S2 | protein_coding | tolerated(0.06) | possibly_damaging(0.773) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
C3orf33 | SNV | Missense_Mutation | novel | c.482N>G | p.Lys161Arg | p.K161R | Q6P1S2 | protein_coding | tolerated(0.28) | benign(0.026) | TCGA-AC-A6IV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C3orf33 | SNV | Missense_Mutation | c.262N>C | p.Glu88Gln | p.E88Q | Q6P1S2 | protein_coding | tolerated(0.06) | possibly_damaging(0.773) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
C3orf33 | SNV | Missense_Mutation | rs200965203 | c.871N>T | p.Arg291Cys | p.R291C | Q6P1S2 | protein_coding | deleterious_low_confidence(0.02) | benign(0.011) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
C3orf33 | SNV | Missense_Mutation | rs547864770 | c.254N>A | p.Arg85Gln | p.R85Q | Q6P1S2 | protein_coding | tolerated(0.29) | benign(0.005) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
C3orf33 | SNV | Missense_Mutation | rs547864770 | c.254N>A | p.Arg85Gln | p.R85Q | Q6P1S2 | protein_coding | tolerated(0.29) | benign(0.005) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
C3orf33 | SNV | Missense_Mutation | novel | c.447N>T | p.Glu149Asp | p.E149D | Q6P1S2 | protein_coding | tolerated(0.14) | benign(0.118) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C3orf33 | SNV | Missense_Mutation | rs200965203 | c.871N>T | p.Arg291Cys | p.R291C | Q6P1S2 | protein_coding | deleterious_low_confidence(0.02) | benign(0.011) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
C3orf33 | SNV | Missense_Mutation | c.529N>T | p.Gly177Cys | p.G177C | Q6P1S2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
C3orf33 | SNV | Missense_Mutation | rs759430996 | c.245N>A | p.Arg82Gln | p.R82Q | Q6P1S2 | protein_coding | tolerated(0.1) | benign(0.267) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |